An engineered fusion protein exploits the efferocytosis pathway to clear amyloid-β (Aβ) from the brain without eliciting the severe inflammatory adverse effects associated with Aβ-targeting antibody-based immunotherapies. In mouse models of Alzheimer’s disease, this approach induced robust clearance of Aβ without inflammation, improved synapse protection, and decreased brain microhemorrhage, which result in superior behavioral recovery.